The findings which were published in Science Immunology identifies new links between the course of the disease and a patient's immune response to it. Current vaccine candidates use portions of the spike protein to stimulate an immune response. Some of these patients mount a vigorous immune response, and others have a more moderate response. It remains to be seen whether the immune response to SARS-CoV-2 vaccination is stronger, or persists longer than that caused by natural infection. Boyd is a co-chair of the National Cancer Institute's SeroNet Serological Sciences Network, one of the nation's largest coordinated research efforts to study the immune response to COVID-19.

Source: Mint December 25, 2020 04:18 UTC